Last updated: July 17, 2026
Novartis AG v. HEC Pharm Co. Ltd. (1:15-cv-00151-LPS): Litigation Summary, Claims at Issue, and Generic Entry Risk
Novartis AG sued HEC Pharm Co. Ltd. in the U.S. District Court for the Western District of Wisconsin under case number 1:15-cv-00151-LPS. The docket identifies a patent-litigation action, but the case materials required to produce a complete litigation summary and enforceability/entry-risk analysis are not present in the provided inputs.
What happened in Novartis AG v. HEC Pharm (1:15-cv-00151-LPS)?
Answer (docket-only summary): Insufficient case record content to state what patents were asserted, what product/ANDA posture triggered the filing, what claims were alleged, the procedural posture, or whether a settlement or dismissal occurred.
Which patents were asserted in 1:15-cv-00151-LPS?
Answer: Not available from the provided information.
Which claims and infringement theories were pled?
Answer: Not available from the provided information.
What was the procedural posture and timeline?
Answer: Not available from the provided information.
What patents protect the Novartis product at issue in this case?
Answer: Not available because the Novartis drug, active ingredient, dosage form, and Orange Book-listed patents tied to the case are not provided.
How many patents are listed in the Orange Book for the relevant Novartis NDA/brand?
Answer: Not available.
Which patent types are typically implicated (composition, formulation, method-of-use, manufacturing)?
Answer: Not available.
When does exclusivity end for the Novartis drug referenced by 1:15-cv-00151-LPS?
Answer: Not available because the NDA/brand and the relevant exclusivity basis are not provided.
Patent expiration vs. FDA exclusivity: what drives the launch window?
Answer: Not available.
Was this an ANDA Paragraph IV challenge, and what generic entry risks exist for HEC Pharm?
Answer: Not available because the ANDA number, listed patents, and Paragraph IV certifications are not provided.
What Paragraph IV certifications were filed?
Answer: Not available.
What stay under 21 U.S.C. § 355(j) likely applied?
Answer: Not available.
How strong is the Novartis patent estate based on claim scope and validity arguments?
Answer: Not available without the asserted patent numbers, claim construction record, invalidity grounds, and any PTAB or other related filings.
What invalidity arguments were raised (anticipation, obviousness, indefiniteness, §101)?
Answer: Not available.
What claim-construction outcomes mattered for infringement?
Answer: Not available.
What settlement or dismissal events occurred in 1:15-cv-00151-LPS?
Answer: Not available because the provided information does not include the settlement terms, consent judgment, dismissal order, or timing of any resolution.
Did Novartis obtain an injunction or favorable adjudication?
Answer: Not available.
Did HEC Pharm receive a license or enter via carve-outs/design-around?
Answer: Not available.
Which court rulings affect generic launch timing (motions, summary judgment, trial outcomes)?
Answer: Not available because the decision documents and hearing dates are not provided.
Were there Daubert rulings, expert exclusions, or summary judgment on infringement/validity?
Answer: Not available.
How does this litigation compare with other Novartis v. generic cases in the same class?
Answer: Not available because the underlying drug/patent family and comparison universe are not provided.
Key Takeaways
- No litigation merits, asserted patents, or outcome details can be stated from the provided inputs for Novartis AG v. HEC Pharm Co. Ltd., 1:15-cv-00151-LPS.
- No entry-risk timing can be calculated without the brand/NDA, Orange Book patents, and Paragraph IV/ANDA posture tied to the case.
FAQs
- What is the asserted patent list for Novartis AG v. HEC Pharm Co. Ltd. (1:15-cv-00151-LPS)?
- What was the ANDA/Paragraph IV posture in 1:15-cv-00151-LPS?
- Did the case end in settlement, dismissal, injunction, or merits judgment?
- What FDA exclusivities would have governed launch timing for the product in dispute?
- What design-around or non-infringement strategies did HEC Pharm pursue (if any)?
References
- (Not provided in the input: no docket documents, complaint, orders, judgments, or Orange Book listings were supplied.)
